William LaRochelle

William is chief scientific officer of Normunity, a venture-backed biotechnology company focusing on immuno-oncology, using antibodies to stimulate the immune response to specific therapeutic targets.

William was previously a subject matter expert at Roche Diagnostic Solutions, where his focus was next-generation sequencing and dPCR applications and medical device workflow solutions that maximize medical value for precision medicine. Prior to this, he was a member of the Roche 454 Sequencing International Business Team and head of key opinion leader relationships, and at CuraGen, he directed the Translational Oncology Program. He has over 35 years of experience in translational research, drug development and next-generation sequencing healthcare applications, beginning with 13 years at the National Cancer Institute.

William has been a member of the CBIF Advisory Committee since 2013 and has served five years on the external advisory board of Yale–University of Connecticut PITCH. He earned his degrees from Manhattan College (BS, biochemistry) and Dartmouth Medical School (PhD, biochemistry) prior to receiving an American Cancer Society Postdoctoral Fellowship to study oncogene signal transduction at the National Cancer Institute. He is an author of over 80 peer-reviewed publications and numerous patents, the editor of the Oncogenomics Handbook, and the recipient of multiple Federal Technology Transfer Awards.